Stimuliver announces further investment to expand its pre-clinical testing and welcomes Professor Simon Best
University of Edinburgh’s Old College Capital invests in Stimuliver ApS
Stimuliver welcomes seasoned global leader Professor Simon Best to the board as an observer
Copenhagen, Denmark, 2023 – Stimuliver ApS, an emerging biotech company developing a first-in-class vascularised tissue implant to treat acute and chronic liver diseases, today announces further investment and welcomes seasoned global leader Professor Simon Best, FRSE, OBE as a board observer.
Old College Capital (OCC) is the University of Edinburgh’s in-house venture investment fund. Its investment will allow Stimuliver to expand its pre-clinical testing and accelerate the development of its liver implant technology. This follows previous investment from BioInnovation Institute and Vækstfonden.
“Stimuliver is bringing knowledge from the University of Edinburgh’s world leading research in liver tissue engineering, into the clinic. We are delighted to support David and the team on this journey, and look forward to seeing the Company’s continued growth”
Andrea Young, Head of Investment at Old College Capital
Stimuliver is pleased to welcome Simon to the board as OCC Observer. His achievements include the development and commercialisation of genetically modified foods in the UK, as well as the commercialisation of nuclear transfer, the underpinning technology behind Dolly the Sheep. Simon’s advice, based on his deep experience in the commercialisation of life sciences, will complement and strengthen the company’s board.
Stimuliver was founded in Denmark by David Hay and Dagmara Szkolnicka and is a spinout from the University of Edinburgh. The company have developed a platform technology that demonstrates vascularised human liver tissue can be administered under the skin, providing long-term host liver support in rodents, and favourably modulates the immune system.
The scalable liver implant technology developed at Stimuliver uses pluripotent stem cells and is not dependent on donor organ availability. This may in the future provide a treatment which is available without waiting time and has the potential to reverse liver disease and prevent hospitalisations.
Stimuliver is incubated at the BioInnovation Institute in Copenhagen.
David Hay, co-founder and CEO said: “We are delighted to receive investment from Old College Capital to develop our pre-clinical testing programmes. This in combination with the appointment of Simon, is key to Stimuliver’s development and bringing implantable human liver tissue to the clinic at scale”
For more information please contact:
Stimuliver
David Hay, CEO
dave@stimuliver.bio
NOTES TO EDITORS
About Stimuliver
Stimuliver is a Danish biotech company with technology from the University of Edinburgh, established to develop a scalable, safe and effective treatment for diseases affecting the liver. The company’s first-in-class, vascularised and immunomodulatory liver tissue implant, aims to treat both acute and chronic liver diseases for which there are limited, and no treatment options currently available. www.stimuliver.bio
About OCC
Old College Capital (OCC) is the University of Edinburgh’s in-house venture investment fund. It aims to support the University’s research, staff and students by investing in high-growth, early stage businesses associated with the University. The fund aims to achieve commercial returns and follows a co-investment model, partnering with experienced private sector investors.
Image Old College Quad CREDIT www.nealesmith.com